

General information about company	
Scrip code*	543998
NSE Symbol*	VALIANTLAB
MSEI Symbol*	NOTLISTED
ISIN*	INE0JWS01017
Name of company	Valiant Laboratories Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	14-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	11-05-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Manufacturing Chemical
Start date and time of board meeting	14-05-2026 15:30
End date and time of board meeting	14-05-2026 17:30
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA

(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?		No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		11-02-2026
Indicate Company website link for updated RPT policy of the Company		https://www.valiantlabs.in/assets/images/investors/related_party_transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		Yes
No. of times funds raised during the quarter		1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	This disclosure is not applicable, as the Company has not defaulted on any of its loans or debt securities.

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr. No.	Details of	Details of the		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are		Additional
		Name	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	In case
1	Valiant Laboratories Limited	Santosh Vora	Executive Director(MD)	Remuneration		27.00	NA			13.50	0.00	0.00	
2	Valiant Laboratories Limited	Paresh Shah	Executive Director(CFO)	Remuneration		15.00	NA			7.50	0.00	0.00	

3	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Investment		16505.80	NA			0.00	16505.80	16505.80	
4	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Sale of goods or services		20000.00	NA			656.49	302.95	660.25	
5	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Any other transaction	Other Reimbursement	200.00	NA			8.43	18.14	13.20	
6	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Any other transaction	Trade Advance Given	1000.00	NA			2746.36	184.39	2930.75	
7	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Purchase of goods or services		1000.00	NA			2059.12	0.37	0.00	
8	Valiant Laboratories Limited	Valiant Organics Limited	Ultimate Holding Company	Purchase of goods or services		30000.00	NA			6508.11	1044.54	5496.06	

9	Valiant Laboratories Limited	Shantilal Vora	Non Executive Director	Any other transaction	Sitting Fees		NA			0.23	0.00	0.00	
10	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Any other transaction	Security Deposit received against Leave & License Agreement executed	96.14	NA			0.00	96.14	96.14	
11	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Purchase of goods or services		700.00	NA			180.46	77.60	31.11	
12	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Any other transaction	Rent Received	500.00	NA			150.00	29.50	0.00	
13	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Any other transaction	Other Reimbursement	1000.00	NA			378.44	57.37	65.81	
14	Valiant Advanced Sciences Private Limited	Valiant Organics Limited	Ultimate Holding Company	Sale of goods or services		5000.00	NA			101.24	0.00	28.22	

15	Valiant Advanced Sciences Private Limited	Dhanvalla bh Ventures LLP	Holding Company	Purchase of goods or services		400.00	ominbus approval granted on 11-11- 2025	9.81	11-11- 2025	37.56	0.00	0.00	
----	---	------------------------------------	--------------------	--	--	--------	---	------	----------------	-------	------	------	--

16	Valiant Advanced Sciences Private Limited	Aarti Pharmalabs Limited	Other Related Party	Sale of goods or services			NA			42.11	0.00	49.69	
17	Valiant Advanced Sciences Private Limited	Alchemie Speciality Chemicals Pvt.Ltd	Ultimate Holding Company	Sale of goods or services		1500.00	NA			108.08	0.00	127.53	
18	Valiant Advanced Sciences Private Limited	J.B.Singh	Executive Director	Remuneration		25.00	NA			8.50	0.00	0.00	
19	Valiant Laboratories Limited	Aarti Pharmalabs Limited	Other Related Party	Sale of goods or services		700.00	NA			490.72	0.00	290.33	
20	Valiant Laboratories Limited	Aarti Industries Limited	Other Related Party	Purchase of goods or services		0.00	NA	14.69	11-02-2026	14.69	0.00	0.00	

21	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Any other transaction	Commission received on Corporate Guarantee provided	0.00	NA	0.20	11-02-2026	0.20	0.00	0.00	
----	------------------------------	---	-------------------------	-----------------------	---	------	----	------	------------	------	------	------	--

disclosure of related party transactions - applicable only in case the related party transaction relates

any financial indebtedness is			Details of the loans, inter-corporate deposits, advances or					
Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorp orate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes

								During the period 1-Oct-25 to 31-March-26, Valiant Advanced Sciences Private Limited entered into a transaction of purchase of goods from Dhanvalla bh Ventures LLP amounting to Rs. 37.56 lakhs, out of which the
--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--